RecruitingNCT05833594

Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma

Anhui Provincial Hospita


Sponsor

Anhui Provincial Hospital

Enrollment

70 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether adding nutritional support (immunonutrition) throughout treatment improves outcomes for patients with locally advanced esophageal squamous cell carcinoma (a type of throat/food-pipe cancer) who are receiving chemoradiation — a combination of chemotherapy and radiation — that cannot be cured by surgery. The goal is to see if better nutrition helps patients tolerate treatment and live longer. **You may be eligible if...** - You are between 18 and 85 years old - You have been diagnosed with esophageal squamous cell carcinoma that cannot be surgically removed - You have not yet received any cancer treatment - Your cancer is at a specific stage confirmed by imaging - Your general health allows chemoradiation (ECOG score 0–2) **You may NOT be eligible if...** - You have a different type of esophageal cancer (such as adenocarcinoma or small-cell) - Your cancer is at a very early or very advanced stage - Your cancer is considered surgically removable - You have previously received chemotherapy or radiation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTWhole-course Immunonutrition Combined With Chemoradiotherapy±ICIs

The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.


Locations(1)

Anhui provincial hospital

Hefei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05833594


Related Trials